Pharmaceutical inhibition of CDK9 transcriptionally regulates MCL-1 mRNA and does not modify proteosomal degradation of MCL-1 in esophageal adenocarcinoma in vitro. Here, MCL1 is linked to esophageal adenocarcinoma.